Phthalate draft report
This article was originally published in The Rose Sheet
Executive Summary
The National Toxicology Program Center for the Evaluation of Risks to Human Reproduction is requesting comments on the draft NTP brief on di-(2-ethylhexyl) phthalate. Comments are due July 5, according to a June 5 Federal Register 1notice. The draft brief evaluates the NTP's conclusions on the potential of DEHP to cause reproductive and developmental toxicity, and provides background information on the substance and findings of a CERHR expert panel. Among conclusions in the draft brief, NTP concurs with the expert panel that there is concern with effects on the development of the male reproductive tract for infants under one year of age. After the comment period and upon finalization, the NTP brief for DEHP will be included in the CERHR monograph for DEHP, center notes. NTP requested data on the ingredient last February, in preparation for a fall expert panel meeting (2"The Rose Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.